<code id='598A07BF46'></code><style id='598A07BF46'></style>
    • <acronym id='598A07BF46'></acronym>
      <center id='598A07BF46'><center id='598A07BF46'><tfoot id='598A07BF46'></tfoot></center><abbr id='598A07BF46'><dir id='598A07BF46'><tfoot id='598A07BF46'></tfoot><noframes id='598A07BF46'>

    • <optgroup id='598A07BF46'><strike id='598A07BF46'><sup id='598A07BF46'></sup></strike><code id='598A07BF46'></code></optgroup>
        1. <b id='598A07BF46'><label id='598A07BF46'><select id='598A07BF46'><dt id='598A07BF46'><span id='598A07BF46'></span></dt></select></label></b><u id='598A07BF46'></u>
          <i id='598A07BF46'><strike id='598A07BF46'><tt id='598A07BF46'><pre id='598A07BF46'></pre></tt></strike></i>

          leisure time

          leisure time

          author:knowledge    Page View:91465
          Vertex Pharmaceuticals - sunset
          Bill Sikes/AP

          Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently, searching for success in a field its own executives have dubbed a graveyard for drug discovery. Detailed data published Wednesday lent support to that quest, with a pair of company-sponsored clinical trials showing an experimental non-opioid therapy reduced pain after surgery.

          The drug, VX-548, blocks signals from pain-sensitive neurons before those electrical messages reach the brain. And in a pair of randomized trials, patients given a high dose of the oral medication after bunion surgery or abdominoplasty (a tummy tuck) reported less pain than those given a placebo. Those taking lower doses of the treatment showed no improvement compared to the placebo group, however.

          advertisement

          While the pain reduction measured by these Phase 2 trials was statistically significant, it’s unclear how meaningful the drug’s benefits were to patients, with a commentary accompanying the study describing the treatment effect as “small.” But the study authors noted that participants on a high dose of VX-548 were less likely to prematurely stop their treatment because it wasn’t working than those on placebo or participants given a combination of two common painkillers, acetaminophen and hydrocodone.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more
          These geoengineering technologies could help combat the climate crisis, scientists say
          These geoengineering technologies could help combat the climate crisis, scientists say

          5:11InthisFeb.1,2023,filephoto,apieceofequipmentcalledadistributorusedtoholdtraysoflimestoneforcaptu

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          When is a doctor not a doctor? Try when patients address women doctors

          AdobeInherinboxontheMayoClinicpatientportal,thedermatologistJamisonHarveyreceivessomemessagesfrompat